Скачать или смотреть FDA to Toughen Drug Ad Rules, Target Misleading Claims and Pricing

The FDA is initiating new rules to remove the 1997 Adequate Provision exception, mandating complete risk and side effect disclosures in drug ads. Enforcement of existing laws is increasing, with warning letters issued to drug companies for misleading advertising. Penalties may include recalls, fines, and criminal charges. Oversight will extend to modern media, including influencer marketing and AI content. This aligns with the Trump administrations pharmaceutical reforms, including the Most Favored Nation pricing policy. Despite these efforts, Americans still spend significantly more on prescriptions than other developed nations. Additional actions aim to limit pharmacy benefit manager power. Critics worry about reduced research investment, but the administration emphasizes transparency and affordability.